Skip to main content
WHERE
East Coast, USA
WHEN
24 – 28 March 2025
Future of Cancer Care – Study Tour 2025

The cost of cancer care is on the rise, yet new therapies—such as cell and gene therapies—continue to dramatically improve patient survival. iFHP’s Future of Cancer Care Study Tour investigates questions around cost-effectiveness and the role of health insurance companies in creating a future where cancer care remains affordable, equitable, and easy to navigate for patients.

The impact of the disease leaves very few people untouched & the desire to have the correct coverage, access and drugs is one of the key drivers for customers to obtain private health insurance.

Based on feedback from our 2024 cohort we have located the first three days of learning at the University of Pittsburgh Medical Centre (UPMC) giving participants the opportunity to spend time within a leading US based payer and hospital group, plus UPMC Enterprises with their portfolio of investments in novel therapeutics and innovative treatments.

There will be a day devoted to payment and contracting, bringing it to life not just through theory, but also through practical workshop sessions on Value-Based Health Care.

The week will end with members attending the Cancer Care at a Crossroads conference held at the New York Genome Center. Members attending our iFHP study tour are automatically registered to attend this conference on March 28. It convenes thought leaders from the US and international, representing every stakeholder — academic medical centers, comprehensive cancer centers, health plans, pharma, health systems/providers, genomics, PBMs, advocacy, government, and the media. It is limited to around 100 senior executives both from oncology and the broader health care ecosystem who come together to discuss the challenges in moving forward and opportunities/innovation in cancer care.

This study tour is perfect for those aiming to enhance their organisation’s understanding of advanced cancer care, navigate current and future reimbursement challenges, and build a network of peers working on similar issues within our network.

Join us in March 2025

Sign up now to get 25% off:
25% off for 2025. Our New Year gift to iFHP members to attend this life-changing Study Tour in the USA. A 25% discount will be applied to those reserving their place on this study tour. The discount will be applied after check out.  The promotional rate is £4120.00 (UK).

The fee includes:

  • 5 nights of accommodation in the U.S (3 nights in Pittsburgh and 2 nights in New York).
  • 4 evening dinners and networking (Wednesday 26th has a free evening for guests in New York)
  • Entrance to the Cancer at a Crossroads Conference in New York on Friday 28th March.

There is one domestic flight between Pittsburgh and New York (Wed 26th) which we recommend guests take American Airlines AA 465 (PIT – LGA) at 16.40 to arrive 18.01. This flight is booked by the attendee along with any international flights. There is also a slightly later flight of AA4484 departing at 19.38. The week commences in Pittsburgh, PA on Monday 24th March and will conclude on Friday 28th in New York.

For further details contact nicola@ifhp.com.

Meet some of our speakers

harold

Harold Miller | President and CEO
Center for Healthcare Quality and Payment Reform

Miller is an internationally-recognized expert on health care payment and delivery reform.  He has written a number of widely-used reports on value-based payment, and his work has appeared in multiple peer-reviewed journals.  He has twice given invited testimony to the U.S. Congress on how to reform healthcare payment, and he served for four years as one of the initial members of the Physician-Focused Payment Model Technical Advisory Committee that was created by Congress to provide advice on alternative payment models.

maria lowe

Maria Lowe | Associate Vice President of Pharmaceutical Intelligence
ICER (Institute for Clinical & Economic Review)

Associate Vice President of Pharmaceutical Intelligence ICER (Institute for Clinical & Economic Review). Maria joined ICER as the Director of Pharmaceutical Intelligence in May 2019, and was promoted to Associate Vice President of Pharmaceutical Intelligence in 2024. In this role, she is responsible for tracking developments in the drug pipeline to advise the ICER team on potential topics of interest.

Vinnie

Dr Vinnie Nambisan | Supportive and Palliative Care Team
HCA

MBChB FRCP BSc (Hons) MA, HCA Supportive and Palliative Care Team. Dr Nambisan spoke at our last study tour and our last cohort felt that his insights into how palliative care, plus also the complex ethics around end of life are delivered were essential to include into our 2025 programme.  

Tuvik Beker

Tuvik Beker | CEO
Pangea Biomed

Enabling deeper understanding of how a tumor would respond to therapy. The technology looks beyond actionable genomic abnormalities by examining the molecular context in which targeted therapies operate.

Adrian-Lee_IPM-560x560

Dr. Adrian Lee | Director, Institute for Precision Medicine
UPMC

Dr. Adrian Lee is Director of the Institute for Precision Medicine, a joint effort by UPMC and the University of Pittsburgh to move biomedical research into personalized well-being and clinical care. The goal of the laboratory is to translate basic cell and molecular research findings into the understanding and treatment of breast cancer. This includes studies on the role of insulin-like growth factors in breast cancer, and identification of biomarkers for this targeted therapy. 

james b

Jamie Bauersmith  | Vice President, Translational Sciences,
UPMC

Vice President, Translational Sciences, UPMC Enterprises. Within UPMC Enterprises, which is the commercialization arm of UPMC, Jamie focuses his time on identifying, analysing and structuring investment opportunities that address unmet therapeutic need and align with UPMC’s vision of bringing life changing medicine to patients.

Who Should Attend

  • Clinical leadership. 
  • Cancer care specialties. 
  • Provider contracting. 
  • Those seeking international insights on treatment and payment models. 
Jenni Noble - Luckhoff (Study Tour 2024 attendee)
Medscheme, South Africa
Co-chair of Medical Effectiveness and High-Cost Drugs iFHP Member network.

The 2024 Oncology Study Tour was led by international experts covering ground-breaking oncology science and technology developments and innovative funding approaches. The final two days were hosted at the state-of-the-art NY Genome Centre, culminating at the Cancer Care at the Crossroads Conference, with presentations by the “who’s who” in global cancer. Next-level networking and exposure to world experts, the tour really is a remarkable opportunity for a crash-course in cutting-edge oncology

Join US